Mark is the founder of PHMR and has developed the company into a successful health economics, pricing and market access consultancy working with a range of top 10 pharma companies. He has a vast amount of experience in the health economics, pricing, reimbursement and market access fields. He also possesses decades of experience with major international pharmaceutical companies and previous work in senior economics research positions.

Jeremy has extensive experience in leading large national, regional and global commercial operations in major pharmaceutical companies. Jeremy brings a wealth of experience to his role at PHMR, providing strategic advice to our clients on commercialisation at all stages of product development, from initial clinical development, to launch, to late lifecycle. He is an expert in commercial strategy development and operational execution. Most recently he led the launches of multiple new diabetes therapies across Europe, Japan, Canada and Australia including novel proteins and biosimilars.

Koonal is a health economist with expertise in stated preference methods, the measurement and valuation of health, and the use of social value judgements in HTA decision making. He has published extensively on HTA policy, particularly on the assessment of cancer and end of life treatments. He has led research and consulting projects for a diverse range of funders and clients including global pharmaceutical companies, health care providers, policy makers, charities and research foundations. Koonal is a member of the EuroQol Group (an international network of researchers that developed the EQ-5D family of instruments) and currently serves on the Group’s Executive Committee.

Kevin is an experienced consultant who has responsibility as a project director managing teams of reviewers in our Newcastle Office. He specialises in systematic literature review methodology and delivers reports to clients that meet international HTA and Cochrane standards. Kevin has completed reviews in clinical efficacy, network meta-analysis, diagnostic accuracy, economic evaluations, health-related quality of life, HTA submissions, guidelines/treatment pathways, and disease epidemiology over a wide range of therapeutic areas.

Megan has extensive experience working across a variety of stages of the drug development process, ranging from analysis of Phase I and III clinical trial data to conducting systematic literature reviews and network meta-analyses for health technology assessment submissions. Megan is familiar with a wide range of common and novel statistical methods used in the pharmaceutical industry and has experience using both frequentist and Bayesian frameworks. She is also proficient with a wide range of programming languages, including SAS, R and WinBUGs.

Rebecca has a background in medical writing and horizon scanning for HTA organisations as part of a national horizon scanning centre. She has experience of conducting systematic reviews, from conception to completion, planning and conducting a clinical trial and preparing oral and poster presentations for a variety of audiences. Rebecca has experience in several disease areas including musculoskeletal health, nutrition and gastrointestinal disease.

Jasmine’s main responsibility at PHMR is in project delivery and management for a range of activities in health economics, outcomes research and market access. Jasmine also contributes to PHMR’s operations and enjoys optimising organisation and communication for our projects to progress rapidly, efficiently and to the highest standards. She has an interest in HTA processes, market access and novel reimbursement frameworks for therapeutics with innovative mechanisms and those based on cell and gene therapies. Jasmine has over 10 years of experience in pharmacology, having previously worked in the UK and Europe for two world leading pharmaceutical companies. She has publications in several peer-reviewed journals and has presented at a range of international conferences. Jasmine has experience in the therapeutic fields of inflammation, allergy, stem cell therapies, oncology, pain and neuroscience.

India joined PHMR having successfully completed her MSc in Health Economics at the University of York. She has since been involved and managed a range of projects at PHMR, including patient reported outcomes analysis and the development and execution of feasibility assessments. She has also supported the building and reviewing of economic models e.g. cost-effectiveness and budget impact models. Before PHMR, India also worked with the Health Economics team at Public Health England, where she submitted her MSc thesis on the investigation of health and social care costs of common chronic conditions in England.

Daniella recently completed an MRes in Biotechnology and Business Enterprise at Newcastle University, during which she conducted a laboratory-based research project investigating the chemical modification of antibiotics used to treat drug-resistant tuberculosis. This experience allowed her to develop skills including performing literature reviews, analysing qualitative and quantitative data, and presenting posters & presentations. Since joining PHMR, Daniella has been involved in the development of literature reviews, scientific reports and global value dossiers.

Louise is a PhD-trained researcher who has extensive experience of conducting systematic reviews and meta-analyses alongside online surveys. She has produced and presented multiple posters and presentations at scientific conferences in the area of nutrition. Prior to joining the PHMR team, Louise completed her thesis at Northumbria University investigating the use of the Mediterranean diet in combination with intermittent fasting in the treatment and prevention of obesity. This data was subsequently used to inform the pilot study of a randomised controlled trial aiming to understand the feasibility of these dietary patterns in daily life and their impact on body composition and cardiovascular biomarkers.

Persefoni has a strong background in the field of medical writing with extensive experience in proofreading, quality assessment of publications and data extractions. Since starting work at PHMR, she has been involved in a range of projects, including preparation of manuscripts, pragmatic literature reviews, early pipeline assessments, global value dossiers and health technology assessment reviews. Persefoni has worked in a range of disease areas, including musculoskeletal diseases, gastrointestinal diseases, mental disorders and haematologic malignancies.

Ewan is a health economist with experience in survival modelling and data extrapolation using a range of traditional and novel methods. He has particular therapeutic experience working in the fields of immuno-oncologics and autoimmune diseases. Ewan also has experience conducting systematic and targeting literature reviews and quantitative data analysis.

Andrew is a health economist who holds an MSc in Health Economics from the University of York. Andrew joined PHMR prior to the successful completion of his thesis on the sensitivity of generic quality of life measures to worsening levels of pain and sleep in adults suffering from rare musculoskeletal diseases. During his time here, he has collaborated on, and project managed, several health outcomes-related projects involving PRO development and utility measurement for a variety of clients. Additionally, he holds a BA in Economics and has previous work experience in the stock brokerage industry.

Aurelie is a health economist with experience of adapting and developing full cost-effectiveness models and budget impact models in various disease areas for HTA submission purposes. Aurelie has also contributed to projects of measurement and valuation of health-outcomes, developing mapping algorithms to generate utility data to inform cost-utility analysis. Prior to joining PHMR she conducted evaluative academic research on health policy in Australia, gaining experience in data analysis using econometrics methods, additionally she has previous work experience in marketing in the pharmaceutical industry.

Anne-Sophie has a wide-ranging experience of health economics and HTA in a range of settings including consultancies, hospitals, pharmaceutical companies and governmental bodies. Such wide-ranging experience has provided her with an in-depth understanding of HTA and reimbursement of pharmaceuticals. Anne-Sophie has developed many HTA submissions for the French HAS (Haute Autorité de Santé) for a range of new therapies including for oncology and orphan designation treatments on behalf of leading pharmaceutical companies. Prior to joining PHMR, Anne-Sophie worked at the Health Products Economics Committee (CEPS) of the French Ministry of Health where she developed valuable insight and experience in pricing processes and negotiations, and evaluation of economic dossiers.

While at PHMR, Ally has been involved in supporting targeted and systematic literature reviews, gathering and interpreting data and communicating complex information in the form of slide decks and scientific reports. She has experience in multiple project types including reviews of clinical efficacy, economic evaluations and burden of illness, HTA process reviews, and production of slide decks for training and educational use. She has disease area experience in oncology, muscle wasting, and rare diseases. Prior to joining PHMR, Ally worked in the pharmaceutical industry as a project manager and holds a PhD in cellular biology and tissue engineering.

Elaine is a medical statistician with extensive experience of statistical input into clinical trials and large public health projects. She possesses experience in analysis of trial data using advanced techniques, merging large patient data sets to assess public health interventions and is fully compliant with Good Clinical Practice (GCP) with up to date certification. This includes contributing to study design, protocol development and the writing of Statistical Analysis Plans (SAPs) as well as the analysis of data using a wide variety of statistical techniques.

Dimitris is a health economist, with broad experience in economic evaluations of therapeutic and diagnostic interventions. He has led and contributed to the conceptualisation and development of long-term models, in a wide range of software, and has completed projects for a diverse range of funders and clients including research foundations, pharmaceutical, and medical device companies.
He also has conducted systematic literature reviews, and diagnostic meta-analyses, and has broad knowledge of HTA methods and processes. His work covers a wide range of disease areas including oncology, mental health, and metabolic diseases.

Catherine’s main responsibility at PHMR is focussed on undertaking pragmatic and systematic literature reviews. Prior to joining PHMR, Catherine worked for 15 years in clinical trial management in an academic and commercial trial environment and was involved in Phase II/III trials across different therapeutic areas. She has developed skills in data monitoring, communication with commercial and academic sponsors and preparing/submitting complex study documentation. During her PhD, she prepared manuscripts for publication and has presented at international conferences.